GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study

GenSight Biologics, a biopharma company focused on gene therapies for retinal diseases, provided updates regarding its GS010/LUMEVOQ® early access programs and the ongoing REVISE study for its lead product candidate. GS010/LUMEVOQ® targets Leber Hereditary Optic Neuropathy (LHON) caused by mutations in the ND4 mitochondrial gene.

In France, the company has successfully initiated its Named Patient Early Access (AAC) program, receiving approvals for applications submitted in February 2026. GenSight is in the final stages of preparing for treatment delivery at 15-20 national hospitals scheduled for mid to late March. The REVISE study, a dose-ranging trial, is also progressing well, with the first patient treated in February and another anticipated to be enrolled soon.

In Israel, a second patient has been approved under the Paid Named Patient Program, following logistical support for treatment slated for the next quarter. The United States has also seen progress, with a second individual investigational new drug (IND) cleared for expanded access, allowing treatment for another patient after an initial IND was approved in October 2025.

Financially, GenSight expects initial payments for French treatments to arrive by the end of March. While the precise timing of further treatments and payments remains uncertain, the projected revenues from these early access programs should sustain the company’s operations past February 2026. Looking forward, GenSight plans to extend its cash runway to support the funding of the upcoming RECOVER Phase III trial.

GenSight Biologics is at the forefront of developing therapies aimed at preserving or restoring vision in patients with severe retinal diseases, with GS010 being administered as a single intravitreal injection designed for lasting visual recovery.

GenSight Biologics (Euronext: SIGHT) is making significant strides with its GS010/LUMEVOQ® gene therapy for Leber Hereditary Optic Neuropathy (LHON), as evidenced by recent regulatory updates regarding early access programs and the ongoing REVISE study. These developments create critical market implications for investors and analysts monitoring biotech stocks.

The successful approval of named patient access in France and the ongoing enrollment in the REVISE study signify a positive trajectory. Early access programs can lead to increased revenue generation and validate the therapeutic’s efficacy, providing GenSight with a robust cash flow. Given expectations for revenues to maintain operational continuity beyond February 2026 and into 2027, shareholders may find this reassuring in the face of ongoing clinical costs.

Moreover, the successful treatment of patients under the Paid Named Patient Program in Israel and the FDA's clearance for expanded access in the USA are strong indicators of strong regulatory relationships and potential market expansion. This suggests that GenSight is on track to build a user base that could be valuable if marketing authorization is granted, ultimately leading to a safer investment climate.

However, caution is warranted. The company remains in a clinical development phase; GS010 has not yet received marketing authorization, which brings inherent risks. Investors should keep an eye on the outcomes of the REVISE study and the forthcoming results from the initial patients treated. These results will be pivotal in determining whether this promising therapy can successfully transition from clinical promise to commercial viability.

In conclusion, the advancements from GenSight Biologics present potential upside for investors, yet market participants should prepare for volatility tied to clinical trial results and regulatory updates. Diversification and a careful review of clinical developments will be essential in navigating this investment landscape.